Jayne Gershkowitz - Amicus Therapeutics Chief Advocate
| FOLD Stock | USD 9.66 0.16 1.68% |
Executive
Jayne Gershkowitz is Chief Advocate of Amicus Therapeutics
| Age | 67 |
| Address | 47 Hulfish Street, Princeton, NJ, United States, 08542 |
| Phone | 609 662 2000 |
| Web | https://amicusrx.com |
Amicus Therapeutics Management Efficiency
The company has return on total asset (ROA) of 0.0116 % which means that it generated a profit of $0.0116 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6709) %, meaning that it created substantial loss on money invested by shareholders. Amicus Therapeutics' management efficiency ratios could be used to measure how well Amicus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 22, 2024, Return On Tangible Assets is expected to decline to -0.28. In addition to that, Return On Capital Employed is expected to decline to -0.13. At present, Amicus Therapeutics' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0.39, whereas Other Assets are forecasted to decline to about 41.8 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Suba Krishnan | Mereo BioPharma Group | 59 | |
| Erik MBA | Ultragenyx | 54 | |
| MS MBA | Kura Oncology | 50 | |
| Yuhong Qiu | Legend Biotech Corp | N/A | |
| Amy Reilly | Dyne Therapeutics | 50 | |
| James Burns | Agios Pharm | 46 | |
| Carole MD | Denali Therapeutics | 51 | |
| Elly MD | Day One Biopharmaceuticals | N/A | |
| Audrey Murphy | Harmony Biosciences Holdings | N/A | |
| Richard MBA | Dyne Therapeutics | 38 | |
| Alan MD | Crinetics Pharmaceuticals | 61 | |
| Ben Strain | Incyte | N/A | |
| Michael Morrissey | Incyte | 60 | |
| Jeffrey Jensen | Inhibrx | N/A | |
| Yen Wing | Biomarin Pharmaceutical | N/A | |
| Amy Wireman | Biomarin Pharmaceutical | N/A | |
| John MBA | Dyne Therapeutics | 61 | |
| Robert McKean | Mineralys Therapeutics, Common | N/A | |
| Paul McInulty | Arvinas | N/A | |
| Peter Chin | Denali Therapeutics | N/A | |
| Liz Gosen | Legend Biotech Corp | N/A | |
Management Performance
| Return On Equity | -0.67 | ||||
| Return On Asset | 0.0116 |
Amicus Therapeutics Leadership Team
Elected by the shareholders, the Amicus Therapeutics' board of directors comprises two types of representatives: Amicus Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Amicus. The board's role is to monitor Amicus Therapeutics' management team and ensure that shareholders' interests are well served. Amicus Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Amicus Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Clark, Chief Officer | ||
| Patrik Esq, Global Officer | ||
| Patrik Florencio, Global VP | ||
| John Crowley, Executive Chairman | ||
| Simon Harford, Chief Officer | ||
| Ellen Rosenberg, General Counsel and Corporate Secretary | ||
| Ellen JD, Chief Secretary | ||
| Samantha Prout, Principal Accounting Officer, Controller | ||
| Jill Weimer, Senior Vice President of Discovery Research and Gene Therapy Science | ||
| Bradley MBA, President CEO | ||
| Andrew Faughnan, Director Relations | ||
| Diana Moore, Head Communications | ||
| Jeffrey Castelli, Vice President - Program and Portfolio Management | ||
| Jayne Gershkowitz, Chief Advocate |
Amicus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Amicus Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.67 | ||||
| Return On Asset | 0.0116 | ||||
| Profit Margin | (0.21) % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 3.06 B | ||||
| Shares Outstanding | 298.81 M | ||||
| Shares Owned By Insiders | 0.73 % | ||||
| Shares Owned By Institutions | 99.27 % | ||||
| Number Of Shares Shorted | 19.9 M | ||||
| Price To Earning | (9.18) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.34) | Revenue Per Share 1.629 | Quarterly Revenue Growth 0.367 | Return On Assets 0.0116 | Return On Equity (0.67) |
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.